300347 泰格医药
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入5,067,615-10.32%7,384,0397,085,4715,213,5383,192,279
减:营业总成本4,026,551-2.79%5,554,1255,156,5443,637,7652,420,862
    其中:营业成本3,097,333-8.12%4,535,5114,277,0082,942,8831,678,036
               财务费用31,371-129.66%(108,324)(158,124)(216,363)88,052
               资产减值损失(10,657)-9.41%(29,725)(2,416)(12,915)5,414
公允价值变动收益(34,412)-104.84%352,771535,8571,815,3901,137,889
投资收益109,158-14.54%338,175102,751312,283283,773
    其中:对联营企业和合营企业的投资收益----105,18339,76314,348(3,508)
营业利润1,084,996-53.07%2,486,9412,582,3993,696,9672,222,312
利润总额1,087,065-53.03%2,488,5332,585,3773,684,5662,218,707
减:所得税费用183,929-35.83%338,606313,652292,864189,707
净利润903,135-55.46%2,149,9272,271,7253,391,7022,029,001
减:非控股权益89,707-39.49%125,077265,173517,539279,226
股东净利润813,429-56.72%2,024,8502,006,5522,874,1631,749,775

市场价值指针
每股收益 (元) *0.940-56.68%2.3402.3203.3102.200
每股派息 (元) *----0.5680.5500.5000.300
每股净资产 (元) *24.3540.89%24.10222.44720.77418.474
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容